Left Arrow IconPreviousRight Arrow IconNextPlus IconExpandMinus IconCollapseMagnifying Glass IconSearch


Hide details for Published in 2017Published in 2017
223ClickClin Rheumatol. 2017 Nov 7. doi: 10.1007/s10067-017-3870-8. [Epub ahead of print]A cross-sectional study of vitamin D levels in a large cohort of patients with rheumatic diseases.Nikiphorou E, Uksila J, Sokka T.
222ClickRheumatology (Oxford). 2017 Aug 1;56(8):1395-1400. doi: 10.1093/rheumatology/kex076.Intercentre variance in patient reported outcomes is lower than objective rheumatoid arthritis activity measures: a cross-sectional study.Khan NA, Spencer HJ, Nikiphorou E, Naranjo A, Alten R, Chirieac RM, Drosos AA, Géher P, Inanc N, Kerzberg E, Ancuta CM, Müller R, Ørnbjerg L, Sokka T.
221ClickAnn Rheum Dis. 2017 Dec;76(12):e49. doi: 10.1136/annrheumdis-2017-211505. Epub 2017 Apr 27. No abstract available.Alternative interpretation of data for recommendations on how to manage rheumatoid arthritis.Pirilä L, Sokka T, Kauppi MJ, Rantalaiho VM, Mervaala E, Puolakka K.
220ClickScand J Rheumatol. 2017 Nov;46(6):425-431. doi: 10.1080/03009742.2016.1266029. Epub 2017 Apr 3.Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.Rannio T, Asikainen J, Hannonen P, Yli-Kerttula T, Ekman P, Pirilä L, Kuusalo L, Mali M, Puurtinen-Vilkki M, Kortelainen S, Paltta J, Taimen K, Kauppi M, Laiho K, Nyrhinen S, Mäkinen H, Isomäki P, Uotila T, Aaltonen K, Kautiainen H, Sokka T.
219ClickClin Exp Rheumatol. 2017 May-Jun;35(3):477-483. Epub 2017 Jan 27.QUEST-RA. The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey.Nikiphorou E, Galloway J, van Riel P, Yazici Y, Haugeberg G, Ostor A, Gogus F, Kauppi M, Sokka T;
218ClickSemin Arthritis Rheum. 2017 Jun;46(6):732-739. doi: 10.1016/j.semarthrit.2016.09.005. Epub 2016 Sep 16.Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort studyAaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, Uutela T, Puurtinen-Vilkki M, Arstila L, Blom M, Sokka T, Nordström D.
217ClickArthritis Rheumatol. 2017 Apr;69(4):866-867. doi: 10.1002/art.40022. Epub 2017 Mar 3. No abstract available.Limited value of the multi-biomarker disease activity assay compared to the Routine Assessment of Patient Index Data 3 (RAPID3) score in the prognosis of important clinical outcomes in rheumatoid arthritis: comment on the article by Fleischmann et al and accompanying editorial by Davis.Pincus T, Block JA, Yazici Y, Bergman MJ, Sokka T.
216ClickScand J Rheumatol Sep;46(5):359-363. doi: 10.1080/03009742.2016.1234641. Epub 2016 Dec 8.Drug survival on TNF-inhibitors in patients with rheumatoid arthritis in Finland.Aaltonen,K, Joensuu, J, Pirilä, L, Kauppi, M, Uutela,T, Varjolahti-Lehtinen, T, Yli-Kerttula,T, Isomäki, P, Nordstrøm, D, Sokka, T:
Hide details for Published in 2016Published in 2016
215ClickClin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S91-S95Go, go, GoTreatIT!Sokka T.
214ClickClin Exp Rheumatol. 2016 Jul-Aug;34(4):694-7A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs.Aaltonen KJ, Turunen JH, Sokka T, Puolakka K, Valleala H.
213ClickSAGE Open Med. 2016 Jun 14;4:2050312116654404.Delivering a one-stop, integrated, patient-oriented service for patients with rheumatic diseasesVäre P, Nikiphorou E, Hannonen P, Sokka T.
212ClickBMC Musculoskelet Disord. 2016 Jun 3;17:246Long-term outcomes of destructive seronegative (rheumatoid) arthritis – description of four clinical casesNikiphorou E, Sjöwall C, Hannonen P, Rannio T, Sokka T.
211ClickJ Rheumatol. 2016 Apr;43(4):699-706.Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid ArthritisRannio T, Asikainen J, Kokko A, Hannonen P, Sokka T.
210Click 2016 Jul-Aug;34(4):641-5Is long-term radiographic joint damage different between men and women? Prospective longitudinal data analysis of four early RA cohorts with greater than 15 years follow-upJ. Asikainen, E. Nikiphorou, K. Kaarela, E. Lindqvist, A. Häkkinen, P. Hannonen, T. Rannio, H. Kautiainen, T. Sokka
209ClickRheumatology (Oxford) 2016 Oct;55(10):1803-11Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register studyJoensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D, Blom M.
208ClickAnn Rheum Dis. 2016 Jan;75(1):3-15.Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceSmolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D.
Hide details for Published in 2015Published in 2015
207ClickN Engl J Med. 2015 Dec 24;373(26):2534-48.Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing SpondylitisBaeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group
206ClickMedicina (Kaunas) 2015;51(1):25-31.Predictors of mortality in patients with rheumatoid arthritis in Lithuania: Data from a cohort study over 10 years.Dadonienė J, Stropuvienė S, Stukas R, Venalis A, Sokka-Isler T.
205ClickExpert Opin Biol Ther. 2015 15(12):1677-83Cost-Effectiveness of Biologics Compared to Conventional Disease-Modifying Antirheumatic Drugs for Treatment of Rheumatoid Arthritis in Finland.Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D, Blom M.
204ClickExpert Opin Biol Ther. 2015 Nov 7:1-7. [Epub ahead of print]Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, Sokka T.
203ClickJ Rheumatol. 2015 Sep;42(9):1542-4.Rheumatoid Arthritis in the 21st Century: Treatment Patterns and Disease Activity States.Nikiphorou E, Rannio T, Sokka T.
202ClickArthritis Res Ther. 2015 Aug 20;17(1):219Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern NorwayHaugeberg G, Hansen IJ, Soldal DM, Sokka T.
201ClickArthritis Res Ther. 2015 May 9;17:117. doi: 10.1186/s13075-015-0646-xUtility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosisOrmseth MJ, Chung CP, Oeser AM, Connelly MA, Sokka T, Raggi P, Solus JF, Otvos JD, Stein CM.
200ClickPLoS One 2015 Apr 8;10(4):e0123582. doi: 10.1371/journal.pone.0123582. eCollection 2015A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritisMichelsen B, Fiane R, Diamantopoulos AP, Soldal DM, Hansen IJ, Sokka T, Kavanaugh A, Haugeberg G
199ClickJ Rheumatol. 2015 Mar;42(3):372-8. doi: 10.3899/jrheum.140853. Epub 2015 Jan 15.Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapyAaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, Valleala H, Rantalaiho V, Pirilä L, Puolakka K, Uusitalo T, Blom M, Konttinen YT, Nordström D.
198ClickNeuroimmunomodulation 2015;22(1-2):89-103. doi: 10.1159/000362735. Epub 2014 Sep 12The past versus the present, 1980-2004: reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 mg/day.Pincus T, Sokka T, Cutolo M.
Show details for Published in 2014Published in 2014
Left Arrow IconPreviousRight Arrow IconNextPlus IconExpandMinus IconCollapseMagnifying Glass IconSearch